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Electronic cigarettes (ecigs) were invented in 2004 in
China and emerged in 2006 in the USA and Europe. Ecigs
were initially manufactured mostly in China, but they are
now also produced in other Asian countries, the USA and
Europe. Tobacco companies entered this competitive
market only recently, initially by purchasing existing
brands (e.g., Blu, Green Smoke, Nicolite, E-Lite). In terms
of public health, the production, use, and promotion of
ecigs are the subject of heated controversies.
Cigarettes kill 6 million people each year globally
(WHO 2104). Preventing tobacco smoking is therefore at
the top of the public and global health agendas, and has led
to an international treaty under the auspices of WHO, the
Framework Convention for Tobacco Control (Shibuya
et al. 2003). Governments have implemented several
interventions aimed at reducing smoking, including tax
increases, smoking bans in public and working areas, and
media campaigns. Major successes have been reported in
many, but not all countries, allowing smoking prevalence
to drop dramatically from, e.g., 80 % in males in the UK in
the 1950s to 22 % nowadays (ASH 2014). However, all
these ‘‘classical’’ interventions are currently facing their
limits, since smoking prevalence is stalling in many
countries, and is increasing in many Asian countries, in
particular among women. Sweden ranks first in OECD
countries with regards to its low prevalence of smoking in
males. It represents an interesting model, since its male
population has been using for decades smokeless tobacco
products named snus. Swedish males exhibit the lowest
rates of lung cancer and oral cancer mortality, two sites of
cancers with high attributable fractions to tobacco smok-
ing. There is a high proportion of snus users in Swedish
males (26 %), and Sweden maintains a high level of
tobacco use in its male population when the 19 % of
smokers are included (Norberg et al. 2011). However, snus
allows for a relatively low smoking prevalence, and high
health benefits. The high level of consumption of smoke-
less tobacco in Sweden is explained by cultural habits,
tradition and a strong marketing, rather than by public
health efforts.
Snus is prohibited in the EU, except in Sweden,
although it is a harm reduction strategy which could be
sensibly considered. Snus represents a natural experiment
in Sweden which tends to demonstrate that smoke kills, not
nicotine, and that smokeless tobacco is much less danger-
ous than cigarettes. We may reasonably assume that a
switch from smoking to smokeless alternatives and to ecigs
and other nicotine vaporizers can be a useful harm reduc-
tion approach, in addition to the existing successful
strategies implemented to fight smoking tobacco.
Those who oppose ecigs see them as a strategy from the
tobacco industry to keep or even enroll new segments of
the population into nicotine addiction, and they also
underline the lack of evidence regarding the long-term
safety of these new devices. Although the latter argument
can be appropriate for drugs, it does not seem to be relevant
regarding alternatives to cigarettes when used by smokers,
because no other product than cigarettes kills half of its
This Commentary is one of three contributions in issue 5 (2014) on
electronic cigarettes. The other contributions are available at
doi:10.1007/s00038-014-0589-z, 10.1007/s00038-014-0598-y.
A. Flahault (&)  J.-F. Etter
Institute of Global Health, Faculty of Medecine, University
of Geneva, Geneva, Switzerland
e-mail: antoine.flahault@unige.ch
A. Flahault
Centre Virchow-Villerme´, Universite´ Sorbonne Paris Cite´,
Paris, France
Int J Public Health (2014) 59:681–682
DOI 10.1007/s00038-014-0597-z
123
users. The relative risk for lung cancer exceeds 20 in daily
smokers compared with non-smokers. The high prevalence
of such a risky behavior explains why lung cancer kills
more people than any other cancer. After one decade of
rapid raise of ecigs and a growing number of published
studies, there is still very little evidence of any risks
associated with their usage (Hajek et al. 2014), suggesting
that if any risk of ecigs is ever discovered, it should not be
as frequent as lung cancer, nor with such strength of
association. Even the strongest opponents to ecigs do not
foresee that the risk of consumption of smokeless tobacco
or ecigs, when used by smokers, may be comparable to the
risk of cigarettes. The problem would therefore be the risk
of ecigs use by young non-smokers, if it lead them to
nicotine addiction and to subsequent smoking. Although
theoretically possible, this risk has not yet been supported
by any study (Hajek et al. 2014). In a publication that
received much media coverage (Corey et al. 2013), the US
Centers for Disease Control and Prevention pretended that
ecigs use by adolescents led to smoking, but in fact, this
study was based on cross-sectional data that cannot be used
to derive causal inferences. In addition, there is no evi-
dence of such an issue with snus in Sweden, or with
nicotine medications, which have been available without
prescription for years. It seems that tobacco is needed to
initiate nicotine addiction.
Another background element which may explain why
many public health scientists and tobaccologists are opposed
to ecigs has an historical origin. When the tobacco industry
launched ‘‘light cigarettes’’, many doctors and scientists
advocated them as less harmful than regular cigarettes, when
in fact they are as or even more dangerous. Cynically, the
tobacco industry was well aware from the beginning of the
absence of harm reduction from light cigarettes. It is note-
worthy that the tobacco industry was not at the origin of the
production of ecigs. They stepped in this market in 2012
only, when Lorillard purchased Blu ecigs. Today, the
tobacco industry intends to lead this market and, using its
influence on regulators, to eliminate competitors. Some
analysts even foresee important losses for this industry if
they keep selling cigarettes only, a reason why this industry
is now investing massively in ecigs and in other new products
(e.g., heated tobacco products). Several countries recently
implemented regulations aimed at controlling ecigs use and
at improving their quality. However, these regulations may
have the undesired effect of fostering large companies,
particularly tobacco and pharmaceutical companies, instead
of small manufacturers, because only large companies can
survive in a strictly regulated environment. This would stifle
innovation and competition, and give the tobacco industry a
leading position in this new market.
Finally, let’s underline the role of citizens and activist
groups. Their influence was critical when the European
Parliament gave up regulating ecigs as medicines in 2013. It
reminds us of the role activists played in the early times of
AIDS, when the medical and scientific communities were
not yet mobilized against this emerging pandemic, the
pharmaceutical industry was not yet committed to looking
for drugs, and politicians were under the influence of various
lobbies, in particular conservative and religious groups.
Ecigs activists are defending their right to use alternatives to
cigarettes and do not intend to let other people, including
public health experts, dictate their lifestyle. They know that
they are escaping from the fatal threat of smoking through
much less harmful alternatives, and some of them are will-
ing to fight hard to make their ‘‘vaping’’ products accessible.
Implementing effective and acceptable policies implies to
better understand the role of non-governmental organiza-
tions and activists, and to involve them in the elaboration of
these policies, as suggested by the WHO Ottawa Charter
almost 30 years ago (Hancock 2013).
The consultation procedure for the new Swiss Tobacco
Law ends on September 12, 2014. This law will regulate
electronic cigarettes and all citizens can participate in this
procedure (Confe´de´ration suisse 2014). The stakes are
high, and it is critical to base regulations on the scientific
evidence and a wide consultation of all stakeholders.
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